Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal. Eli Lilly is also eligible to receive milestone payments of up to $450 million based on sales of Baqsimi, the only nasally administered drug to treat severely low blood sugar in people with diabetes., Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal. Eli Lilly is also eligible to receive milestone payments of up to $450 million based on sales of Baqsimi, the only nasally administered drug to treat severely low blood sugar in people with diabetes., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way